2 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Withdrawn 2 |
| Phase 2 | 2 | Withdrawn 2 |
Follow CD22 Positive: new trials by email Literature Review of CD22 Positive trials Research Report on CD22 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-01-21 | 2022-01-28 | |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 |
Burkitt Lymphoma (2) · Disease Progression (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1)
DNA Virus Infections (2) · Epstein-Barr Virus Infections (2) · Hemic and Lymphatic Diseases (2) · Herpesviridae Infections (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Infections (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Tumor Virus Infections (2) · Virus Diseases (2)
Cyclophosphamide (1) · Inotuzumab Ozogamicin (1) · Vincristine (1) · fludarabine (1)
M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (2)
Eunice S Wang (1) · Jin S Im (1)
P30CA016672 (1)